Casper Joseph Michael 4

What Happened

• Casper Joseph Michael, Chief Operating Officer of NRX Pharmaceuticals (NRXP), was granted 100,000 stock options (reported as a derivative award) on January 27, 2026. The Form 4 records the acquisition price as $0.00, which reflects an awards/grant reporting convention rather than a cash purchase.

Key Details

• Transaction date: January 27, 2026; Form 4 filed February 17, 2026 (filed late relative to the typical 2-business-day Form 4 deadline).
• Transaction type: Grant / award of stock options (derivative).
• Amount: 100,000 options; price shown: $0.00 (award reporting).
• Vesting (per footnote): 33.3% vests June 1, 2026; 33.3% vests December 1, 2026; remaining 33.3% vests December 1, 2027.
• Shares owned after transaction: not specified in the filing.
• Footnote: Grants were made under the issuer’s 2021 Omnibus Incentive Plan (see vesting schedule above).

Context

• This filing reports an option grant (executive compensation), not an open-market purchase or sale. Option grants give the right to buy shares later at an exercise price (the filing’s $0.00 line does not disclose any exercise price or intrinsic value). Such awards are common for executives and do not, by themselves, indicate immediate buying or selling intent; any future exercise or sale would generate additional filings. The late filing simply updates disclosure of the earlier grant.